rc 3095 has been researched along with Cancer of Pancreas in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hong, SK; Yang, KX; Yang, SY; Yin, SH | 1 |
| Cai, RZ; Ertl, T; Groot, K; Horvàth, JE; Qin, Y; Schally, AV | 1 |
| Cai, RZ; Ertl, T; Halmos, G; Qin, Y; Schally, AV | 1 |
| Groot, K; Halmos, G; Schally, AV; Szepeshazi, K | 1 |
| Cai, RZ; Milovanovic, S; Radulovic, S; Schally, AV; Szepeshazi, K; Szoke, B | 1 |
5 other study(ies) available for rc 3095 and Cancer of Pancreas
| Article | Year |
|---|---|
RC-3095, a gastrin-releasing peptide receptor antagonist, synergizes with gemcitabine to inhibit the growth of human pancreatic cancer CFPAC-1 in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Bombesin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Peptide Fragments; Receptors, Bombesin; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Antagonists of bombesin/gastrin-releasing peptide inhibit growth of SW-1990 human pancreatic adenocarcinoma and production of cyclic AMP.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bombesin; Cell Division; Cyclic AMP; Gastrin-Releasing Peptide; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Peptide Fragments; Peptides; Tumor Cells, Cultured | 1995 |
Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro.
Topics: Animals; Antineoplastic Agents; Bombesin; DNA, Neoplasm; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Pancreatic Neoplasms; Peptide Fragments; Receptors, Bombesin | 1994 |
Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters.
Topics: Animals; Body Weight; Bombesin; Carcinoma; Cricetinae; Dose-Response Relationship, Drug; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Female; Gastrin-Releasing Peptide; Gastrins; Growth Hormone; Insulin-Like Growth Factor I; Mesocricetus; Nitrosamines; Pancreatic Neoplasms; Peptide Fragments; Peptides; Receptors, Bombesin; Receptors, Neurotransmitter | 1993 |
Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters.
Topics: Adenocarcinoma; Amino Acid Sequence; Animals; Antineoplastic Agents; Bombesin; Carcinogens; Cell Membrane; Cricetinae; ErbB Receptors; Female; Gastrins; Mesocricetus; Molecular Sequence Data; Nitrosamines; Organ Size; Pancreatic Neoplasms; Peptide Fragments; Receptors, Bombesin; Receptors, Neurotransmitter; Somatostatin | 1991 |